Trials / Completed
CompletedNCT01997164
Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular ("Wet") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)
An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to investigate the safety and tolerability of intravitreal (IVT) REGN910-3 and IVT REGN910 in patients with neovascular age-related macular degeneration (AMD), and separately in patients with diabetic macular edema (DME).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | REGN910-3 | |
| DRUG | REGN910 | |
| DRUG | Intravitreal Aflibercept Injection (IAI) |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2013-11-27
- Last updated
- 2016-01-12
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01997164. Inclusion in this directory is not an endorsement.